Evommune (EVMN) Stock Price, News & Analysis

Company Overview

Evommune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated inflammatory diseases. The company uses its research platform to identify and advance therapies designed to address underlying mechanisms of chronic inflammation rather than only managing symptoms.

Evommune’s pipeline has included soquelitinib, an oral, selective inhibitor of inducible T-cell kinase (ITK) being investigated for inflammatory and immune-related conditions. The company’s development programs have focused on diseases such as atopic dermatitis and other dermatologic or systemic inflammatory disorders, although programs and indications may change as clinical research progresses.

The company’s activities are centered on drug discovery and clinical development, with potential commercialization dependent on successful clinical trials and regulatory approvals. Evommune is headquartered in the United States and develops therapies intended for patients with significant unmet needs in immune-mediated disease.

Key Stats

• Today's Range: $9.20 to $9.75
• 50-Day Range: $9.34 to $14.99
• 52-Week Range: $9.20 to $33.20
• Volume: 1.49 million shs
• Average Volume: 602,730 shs
• Market Capitalization: $350.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.33
• Consensus Rating: Moderate Buy

Evommune Stock Analysis - MarketRank™

Evommune scored higher than 65% of companies evaluated by MarketBeat, and ranked 273rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evommune has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 10 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Evommune has a consensus price target of $33.33, representing about 245.3% upside from its current price of $9.65.

Amount of Analyst Coverage

Evommune has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Evommune are expected to decrease in the coming year, from ($3.16) to ($3.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evommune is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evommune is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evommune has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.46% of the float of Evommune has been sold short.

Short Interest Ratio / Days to Cover

Evommune has a short interest ratio ("days to cover") of 11.63, which indicates bearish sentiment.

Change versus previous month

Short interest in Evommune has recently decreased by 7.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evommune does not currently pay a dividend.

Dividend Growth

Evommune does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: -0.28

News Sentiment

Evommune has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Evommune this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for EVMN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Evommune to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Selling Shares

Cluster Insider Buying

2 insiders have purchased shares of Evommune in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Evommune insiders have sold 347.83% more of their company's stock than they have bought. Specifically, they have bought $146,260.00 in company stock and sold $654,997.00 in company stock.

Percentage Held by Insiders

31.10% of the stock of Evommune is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Evommune has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:EVMN
• CIK: 2044725
• Web: www.evommune.com
• Phone: (650) 223-7745
• Fax: N/A
• Employees: 48
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Evommune: $33.33
• High Price Target: $55.00
• Low Price Target: $18.00
• Potential Upside/Downside: +245.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.87 million
• Net Margins: N/A
• Pretax Margin: -946.68%
• Return on Equity: -62.63%
• Return on Assets: -40.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.68
• Quick Ratio: 11.68

Sales & Book Value

• Annual Sales: $13 million
• Price / Sales: 26.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.52 per share
• Price / Book: 1.48

Miscellaneous

• Outstanding Shares: 36,290,000
• Free Float: 25,005,000
• Market Cap: $350.34 million
• Optionable: N/A
• Beta: N/A